Zhao J, Zeng Y, Shen X, et al. - This meta-analysis showed superiority of early initiation of Sacubitril/Valsartan, relative to angiotensin-converting enzyme inhibitor (ACEI), in decreasing the risks of major adverse cardiac events (RR: 0.61) and increasing left ventricular ejection fraction when administered in patients following acute myocardial infarction.

• Four Databases and relevant grey literature were explored.

• Studies from inception to July 2, 2021 were identified.

• Four studies comprising 6,154 patients were included.

• Sacubitril/Valsartan showed no clear benefit than ACEI for other outcomes (the incidences of cardiac death, the heart failure hospitalization, the myocardial infarction and the adverse side effects).